乳腺癌表型影响新辅助化疗后MRI疗效评估
本回顾性研究纳入219例浸润性乳腺癌患者,于新辅助化疗前后行乳腺MRI并与病理金标准对照。MRI诊断病理完全缓解的准确率80%、敏感度69%、特异度87%,治疗前MRI呈非肿块强化是MRI与病理缓解不一致率较高的唯一相关因素(p=0.003)。
要点
- MRI诊断新辅助化疗后病理完全缓解的准确率80%,敏感度69%、特异度87%。
- 治疗前MRI非肿块强化与MRI-病理缓解不一致率较高相关(p=0.003)。
- MRI与病理评估完全缓解的例数分别为76例(35%)和85例(39%)。
核心结论
- MRI在新辅助化疗后预测病理完全缓解具有良好准确率,但治疗前MRI非肿块强化会降低MRI评估治疗反应的诊断效能。
研究设计与样本
- 回顾性研究,纳入219例浸润性乳腺癌患者,新辅助化疗前后各行一次乳腺MRI,以手术标本病理检查为金标准。
关键影像表现/征象
- 新辅助化疗后MRI分析显示76例(35%)完全缓解。
- 新辅助化疗后手术标本病理分析检出85例(39%)病理完全缓解。
- 治疗前MRI存在非肿块强化是与MRI-病理缓解不一致率较高唯一有统计学相关的因素(p=0.003)。
诊断标准与关键数值
- 以浸润性乳腺病变消失定义为病理完全缓解。
- MRI诊断病理完全缓解的准确率80%,敏感度69%,特异度87%。
- MRI诊断病理完全缓解的阳性预测值78%,阴性预测值82%。
临床应用与阅片要点
- 解读新辅助化疗后乳腺MRI时,需结合治疗前MRI是否呈非肿块强化来理解其预测病理完全缓解的效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate which factors may influence magnetic resonance imaging (MRI) performance in the detection of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC).
METHOD: This retrospective study included 219 patients diagnosed with invasive breast carcinoma who underwent breast MRI before and after NAC. The MRI findings were compared to gold standard pathological examinations. Resolution of invasive breast disease was defined as pCR.
RESULTS: The mean age of our cohort was 48 years (range: 20-85). The molecular subtypes included: Luminal B/Her-2 negative (n = 89; 40%), triple-negative (n = 69; 32%), Luminal B/Her-2 positive (n = 43; 20%), and Her-2 overexpression (n = 18; 8%). MRI analysis after NAC showed complete response in 76 cases (35%), while pathological analysis of surgical specimens after NAC detected pCR in 85 cases (39%). The accuracy of MRI in diagnosing pCR was 80%, with 69% sensitivity, 87% specificity, and positive and negative predictive values of 78% and 82%, respectively. The only factor statistically associated with a higher discordance rate between MRI and pathologic response was the presence of non-mass enhancement at pre-treatment MRI (p = 0.003).
CONCLUSIONS: MRI demonstrated good accuracy in predicting pCR after NAC among the breast cancer patients examined. However, non-mass enhancement at pre-treatment MRI negatively affected the diagnostic performance of MRI in assessing treatment response after NAC.
引用
- Negrão EMS, Souza JA, Marques EF, et al. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy. Eur J Radiol. 2019. PMID: 31610321. doi:10.1016/j.ejrad.2019.108701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。